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CONCLUSIONS: It proved practical and feasible to use DCEs
as a basis of quality weights within a programme speciﬁc QALY
framework. Important areas for future research include devel-
oping proﬁle measures into index measures, ensuring realistic
designs that satisfy both statistical and respondent efﬁciency 
and anchoring at full health and death for use within a QALY
framework.
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OBJECTIVES: Age-related macular degeneration (AMD) is the
leading cause of blindness in the developed countries and
accounted for 8.7 million cases of blindness around the world in
2002. Insufﬁcient documentation of the impact of AMD on
patients and their caregivers limits our understanding of the
disease burden. The objective of this study is to document the
humanistic and economic impact of exudative (wet) AMD on
elderly subjects and compare it to a population group not
affected by the disease. METHODS: This is a multinational,
cross-sectional, observational study of self-reported functional
health and disease burden among elderly subjects with and
without subfoveal, exudative AMD. Each of the ﬁve participat-
ing countries, Canada, France, Germany, Spain, and the UK, will
recruit 100 bilateral AMD patients and 100 controls. The
primary objective is to compare the difference in humanistic
impact as measured by the National Eye Institute Visual Func-
tion Questionnaire (NEI-VFQ25) between AMD patients and
control group of similar age patients in general medical care.
Other end points include assessment of the disparity in health-
related quality of life burden due to wet AMD compared to non-
AMD controls using the EuroQol and Hospital Anxiety and
Depression Scale. Information on resource utilization and eco-
nomic impact of AMD on patients and caregivers will be col-
lected form physicians and patients. RESULTS: Data collection
began in April 2005 and is expected to complete by November
2005. Final analysis will use standard bivariate and multivariate
methods to explore relationships between severity of AMD and
sociodemographic characteristics, health-related quality of life,
depression, falls, and resource utilization variables. Summary
analysis will be conducted in aggregate and by country. CON-
CLUSIONS: Analysis of a wide range of factors affecting AMD
patients will provide useful guidance to health care providers,
payers, and AMD support groups when determining the beneﬁts
of emerging therapies for wet AMD.
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OBJECTIVE: To assess the impact of best and worst eye visual
acuity (VA) on vision-speciﬁc health-related quality of life
(HRQol) and utility in patients with wet Age-Related Macular
Degeneration (AMD) METHODS: A cross-sectional study was
carried out in three European countries: France, Germany, Italy.
Patients were enrolled when they visited a participating retina
specialist. VA at diagnosis and at inclusion was collected. Two
HRQoL instruments were administered at the visit day: the
National Eye Institute Visual Function Questionnaire—25 items
(NEI-VFQ-25), and the Health Utility index (HUI). Patients were
stratiﬁed into four groups of severity using two VA thresholds,
20/40 for the best eye (BE) and 20/200 for the worst eye (WE).
Analysis of variance was performed on QoL and utility scores to
estimate the impact of each eye adjusted on age, gender and
country. RESULTS: 360 patients were included, mainly females
(60%). Mean age and time since AMD diagnosis was respec-
tively 77 years and 2.3 years. At inclusion, mean VA was 0.49
LogMar for BE and 1.0 LogMar for WE. HUIs mean scores
decreased with severity from 0.62 to 0.39 for HUI3 and from
0.76 to 0.63 for HUI2. For both utility indexes, scores were
mainly linked to BE VA. The NEI-VFQ-25 scale also exhibits a
decreasing trend in the global score as VA decreases. Mean global
score varied from 67.0 for the less severe group to 47.0 for the
more severe one. Global NEI-VFQ-25 score was signiﬁcantly
affected by BE and WE VA (BE p < 0.0001; WE p = 0.0306).
This contribution was also observed for the General vision, 
distance vision, driving, and mental health subscales. CON-
CLUSION: HRQoL and utility scores decreased with the dete-
rioration of VA. BE VA and WE VA is two independent factors
of vision-related QoL. Vision preservation in both eyes should
maintain QoL for AMD patients.
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OBJECTIVES: To determine and compare utility values (patient
preferences) associated with dry eye disease with other disease
utilities. METHODS: Forty-four patients with mild to severe dry
eye attending a tertiary specialist dry eye clinic in the UK were
surveyed via interactive utility assessment software. Utility values
were measured by the time trade-off (TTO), standard gamble
(SG), and rating scale (RS) methods and adjusted to scores from
1.0 = perfect health to 0.0 = death. Patients reported utilities for:
self-reported current dry eye status, self-reported current comor-
bidities, various dry eye severities, and binocular and monocu-
lar painful blindness. Visual functioning and ocular symptoms
were assessed by the 25-Item National Eye Institute Visual 
Function Questionnaire and the Ocular Surface Disease Index.
Patient dry eye severity was independently classiﬁed by patient
and physician assessments. Pearson correlation coefﬁcients were
computed for patients’ self-reported dry eye utility and physi-
cian-reported severity. Agreement between self-reported and
physician-reported patient severity was analyzed (Kappa).
RESULTS: Patients reported higher utilities for their current dry
eye condition than for monocular and binocular blindness
(SG:0.84 > 0.60 > 0.51; TTO:0.67 > 0.43 > 0.38; RS:0.55 > 0.37
> 0.24). Using TTO, the mean score for asymptomatic dry eye
(0.68) was similar to that for “some physical and role limitations
with occasional pain” and severe dry eye requiring surgery
scored (0.56) similarly to hospital dialysis (0.56–0.59). Utilities
described by patients of other dry eye severity levels were similar
for patients self-reported as mild to moderate versus those self-
